After more than 50 years of human use, no adverse effects have
been observed. Furthermore, intensive biological, toxicological,
pharmacological and analytical research was conducted for the
purpose of registering it as a medicine in France and other
countries in Europe. In one study, daily doses of up to 35,000
mg for six months were determined to cause no adverse effects.
Flavay® was also clinically tested, in particular for
all sorts of symptoms related to venolymphatic insufficiencies.
The spin-off is a goldmine of data: The rigorous testing to
meet the standards required by the health ministries of France,
Germany and other European countries demonstrate that Flavay®
is highly bioavailable, nontoxic, nonallergenic, noncarcinogenic,
nonmutagenic, will not cause birth defects, and is completely
safe.
Dr. Masquelier’s unequaled manufacturing process has been
conducted for half a century at the very same facilities in
France, and under the control of French Pharmaceutical inspection.
These time-proven standards serve as a reliable assurance of
the quality, consistency, bioavailability and safety of Flavay®.
Who can take Flavay®?
Everyone, from the very young to the elderly. Flavay®
has no known contraindications (conditions under which it should
not be used). Flavay® is completely safe and nontoxic.
In fact, clinical trials have been conducted in which pregnant
women (troubled by varicose veins and other circulatory problems
in the legs) safely used Flavay®.
FlavayT may enhance the anticoagulant effects of anticoagulant
drugs (such
as Coumadin or heparin). Notify your physician if you are taking
anticoagulant drugs, as a blood test may indicate to your physician
that the
drug dose may be reduced if FlavayT or Flavay PlusT is being
consumed. This is because FlavayT has been shown to normalize
the reactivity ("stickiness") of blood platelets.
[More...]
Safety of Flavay Plus®
The essential vitamins and minerals in Flavay Plus® are
naturally-derived and completely safe when used as directed
on the label.
Flavay Plus® includes phosphatidyl serine, derived from
soy lecithin, which has been proven safe in standard toxicology
tests. From the large number of human studies conducted, phosphatidyl
serine has developed a flawless safety record and proven compatible
with a wide array of medications.
Statements made herein have not been
evaluated by the Food and Drug Administration. These products are not intended
to diagnose, treat, cure or prevent any disease.
Masquelier, J. Plant extract
with a proanthocyanidins content as a therapeutic agent having
radical scavenging effect and use thereof. U.S. Patent No. 4,698,360,
1987.
Masquelier, J. A lifetime devoted to OPC and Pycnogenols. Alfa
Omega Editrice, Pub., 1996.
Schwitters, B., Masquelier, J. OPC in practice. Alfa Omega Editrice,
Publishers, 1995.
Yu, C. L. et al. Mutagenicity of proanthocyanidins. Food Chem.
Toxicol. 25(2):135-9, 1987.
Pantaleoni, G.C., Quaglino, D. Univerisity of Aquila Pharmacol-Toxicologica
Report, 1971.
Laparra, J., et al., Acta Therapeutica, 4:233, 1978.
Acute and chronic toxicity tests. International Bio-Research,
Inc., Hanover, Germany, 1967-1971.
Dumon, M., Michaud, J., Masquelier, J. Proanthocyanidin content
in vegetable extracts to be used in the preparation of medicines.
Bull. Soc. Pharm. Bordeaux, 129:51-65, 1990.
Kidd, P.M. Phosphatidylserine: the nutrient that accelerates all
brain functions and counters Alzheimer’s disease: Keats Pub.
1998.
Cenacchi T, et al. Cognitive decline in the elderly: A double-blind,
placebo-controlled multicenter study on efficacy of phosphatidylserine
administration. Aging, 5: 123–133, 1993.
Maggioni M, Picotti GB, Bondiolotti GP et al. Effects of phosphatidylserine
therapy in geriatric patients with depressive disorders. Acta
Psychiatr Scand. 81: 265–270, 1990.
Brambilla, F., Maggioni, M., Panerai, A.E., et al. Beta-endorphin
concentration in peripheral blood mononuclear cells of elderly
depressed patients—effects of phosphatidylserine therapy.
Neuropsychobiology, 34: 18–21, 1996.
Monteleone P., Maj M., Beinat L., Natale M., Kemali, D. Blunting
by chronic phosphatidylserine administration of the stress-induced
activation of the hypothalamo-pituitary-adrenal axis in healthy
men. Eur J Clin Pharm, 43: 385–388, 1992.
Cenacchi T, et al., “Cognitive decline in the elderly: A
double-blind, placebo-controlled multicenter study on efficacy
of phosphatidylserine administration.” Aging, 5, 123-133,
1993
Funfgeld, E.W., Baggen, M., Nedwidek, P., Richstein, B., Mistlberger,
G. Double-blind study with phosphatidylserine (PS) in parkinsonian
patients with senile dementia of Alzheimer’s type (SDAT).
Prog Clin Biol Res, 317:1235-46, 1989.
Le Bars, P.L., Katz, M.M., Berman, N., Itil, T.M., Freedman, A.M.,
Schatzberg, F.A. A placebo-controlled, double-blind, randomized
trial of an extract of ginkgo biloba for dementia. Journal of
the Amer Med Assoc, 278 (16):1327-32, 1997.
